Digoxin Short Term Treatment Assessment Randomized Trial in AHF
NCT ID: NCT02544815
Last Updated: 2023-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
500 participants
INTERVENTIONAL
2023-05-01
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Digoxin processes many characteristics of a beneficial drug for heart failure, however recent publications has rose concerns about its safety profile and therefore decreasing its use.
Whether digoxin is efficient and safe in short term treatment of acute heart failure is a question that should be studied.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The majority of patients appear to respond well to initial therapies consisting of loop diuretics and vasoactive agents. however, this treatments failed to decrease post-discharge mortality and readmission rates which represent the most important goal in AHFS.
In the last few years, many drugs has been tested in AHFS setting trying to adress this issue, however results has been disappointing in term of efficacy and / or safety.
Although evidence supports the beneficial effects of digoxin on hemodynamic, neurohormonal, and electrophysiological parameters in patients with CHF, recent publications has rose concerns about its safety profile and therefore decreasing its use.
The effects of digoxin alone or in combination with other vasodilators are seen within few hours of its administration and result in increased cardiac output, decreased pulmonary wedge pressure, increased ejection fraction, and improved neurohormonal profile without changes in blood pressure.
All this findings made us rose the question of whether digoxin is effective or not in short term treatment of acute heart failure ? Additionnel treatments for AHF were given according left to ACCF/AHA for the managementof heart failure .
Blood testing for scanner digoxin magerments will be confirmed at H8, h24 and H72 after the post protocol treatment admession treatment administration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Digoxin
Oral digoxin 0.25 mg: one pill per day for 30 consecutive days.
Digoxin
Digoxin 0.25 mg pills
Placebo
Oral placebo for 30 days.
Placebo
Placebo pills
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Digoxin
Digoxin 0.25 mg pills
Placebo
Placebo pills
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female aged ≥18 years old.
* Admitted for acute heart failure defined by the presence of dypnea at rest or with minimal exertion , pulmonary congestion on chest radiograph ; and increased natriutic peptide concentrations ( BNP \>=350 pg/ml) or NTproBNP \>=1400 pg/ml ) .
* Able to be randomized within 12 hours from presentation to the hospital.
Exclusion Criteria
* Known severe or terminal renal failure.
* Previous hepatic impairment.
* Major surgery within 30 days.
* Hematocrit \< 25%.
* Alteration of consciousness GCS \< 15
* Critically ill patients needing immediate mechanical hemodynamic of ventilatory support.
* Confirmed or suspected diagnosis of ACS within 45 days before inclusion.
* Severe arrhythmias including significant sinoatrial or atrioventricular blocks or WPW syndrome.
* Implantable cardiac devices including pacemakers and defibrillators.
* Hypertrophic obstructive, restrictive, or constrictive cardiomyopathy.
* Noncardiac pulmonary edema, including suspected sepsis.
* Severe pulmonary disease
* Significant stenotic valvular disease .
* Hyperkalemia \> 5.5 mmol /L .
* Administration of an investigational drug or implantation of an investigational device or participation in another trial within 30 days before screening.
* Previous treatment with digoxin within 15 days before inclusion or contra-indications to digoxin.
* Inability to follow instructions or comply with follow-up procedures.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Monastir
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pr. Semir Nouira
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nouira Semir, Professor
Role: PRINCIPAL_INVESTIGATOR
University Hospital of Monastir
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sahloul University Hospital
Hammam Sousse, Sousse Governorate, Tunisia
Fattouma Bourguiba University Hospital
Monastir, , Tunisia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Boukef Riadh, Professor
Role: primary
Nouira Semir, Professor
Role: primary
nasri Bzeouich, MD
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L; International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005 Dec 20;112(25):3958-68. doi: 10.1161/CIRCULATIONAHA.105.590091. No abstract available.
Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997 Feb 20;336(8):525-33. doi: 10.1056/NEJM199702203360801.
Hashim T, Elbaz S, Patel K, Morgan CJ, Fonarow GC, Fleg JL, McGwin G, Cutter GR, Allman RM, Prabhu SD, Zile MR, Bourge RC, Ahmed A. Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. Am J Med. 2014 Feb;127(2):132-9. doi: 10.1016/j.amjmed.2013.08.006. Epub 2013 Sep 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Digoxin - START - AHF
Identifier Type: -
Identifier Source: org_study_id